الفهرس 
PRETERM BIRTHOnly 14 pages are availabe for public view
 |  | from | 173 |  |  |
| | | from | 173 | | |
Abstract
Preterm birth is the major cause of neonatal mortality and morbidity. A history of a prior spontaneous PTB remains the greatest risk factor for spontaneous PTB, These high- risk women have been the focus of recent trials for the prevention of recurrent prematurity.
Several trials have shown a reduction in spontaneous PTB using various formulations of progesterone, offering progesterone supplementation to women with a prior spontaneous PTB is now recommended by American College of Obstetricians and Gynecologists.
The study subjects were randomized to receive twice daily capsules of either 100 mg of OMP or placebo from enrollment (14–18 weeks) until 36 weeks or delivery, whichever occured first. The patients and medical staff were blinded to the study medication allocation.
Study design:
The study was designed as randomized-controlled interventional prospective study. Participants will be randomly assigned into two parallel groups:
group A (progesterone group) (n=106) received oral micronized progesterone capsules (Utrocare®, October Pharma, Sixth of October city, Egypt).
group B (the placebo group) (n=106) received identical oral capsules (made by the same company, October Pharma).
There was a statistically significant reduction in the rate of preterm birth between the two groups from 63.7%in placebo group, compared with 44.7% in progesterone group.
There was high significant increase in the average gestational age for those who had preterm birth from mean (33.40±2.44) weeks in placebo group compared to mean (35.17±2.07) weeks in the progesterone group.
Although we used the oral route of progesterone administration, our results were similar to those of most compared studies which used the vaginal or intramuscular routes according to prolongation of gestational age at delivery, reducing of rate of preterm birth and improving of the neonatal outcome.